Long-Term Efficacy and Safety of Natalizumab in an Italian Pediatric Cohort With MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study
Neurol. Sci. 2022 Jul 04;[EPub Ahead of Print], D Baroncini, A Ghezzi, C Guaschino, L Moiola, M Filippi, A Ianniello, C Pozzilli, R Lanzillo, V Brescia-Morra, M Margoni, P Gallo, G Callari, L Grimaldi, G Lus, M Calabrese, M Simone, GA Marfia, S Rasia, D Cargnelutti, G Comi, M ZaffaroniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.